X-CELLENT NATRILIX SR VERSUS CANDESARTAN AND AMLODIPINE IN THE REDUCTION OF SYSTOLIC BLOOD PRESSURE IN HYPERTENSIVE PATIENTS

Name: X-CELLENT NATRILIX SR VERSUS CANDESARTAN AND AMLODIPINE IN THE REDUCTION OF SYSTOLIC BLOOD PRESSURE IN HYPERTENSIVE PATIENTS (US 79006517)
Creator: United States Patent and Trademark Office

USPTO (United States) · Serial 79006517

Status: cancelled
Status updated: 22 September 2014
Filing date: 21 September 2004
Registration date: 21 August 2007
Nice classification: 5, 42, 44
Owner: BIOFARMA
Owner country: FR
Raw status code: 404

Authoritative source

The official US trademark record is at USPTO TSDR (serial 79006517) ↗. Where our data differs from the USPTO record, theirs is correct.

See methodology for refresh cadence + status normalisation. See sources for licensing.